Skip to main content
Acticor Biotech logo

Acticor Biotech — Investor Relations & Filings

Ticker · ALACT ISIN · FR0012519668 LEI · 969500K433EK1G89EV95 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2022-03-03 Declaration of Voting R…
Country FR France
Listing PA ALACT

About Acticor Biotech

https://www.acticor-biotech.com

Acticor Biotech is a clinical-stage biopharmaceutical company that originated as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is dedicated to developing innovative treatments for thrombotic diseases, with a primary focus on the acute phase of ischemic stroke. Its lead drug candidate, glenzocimab, is a humanized monoclonal antibody fragment designed to target platelet glycoprotein VI (GPVI), a key receptor involved in thrombosis. The therapeutic approach aims to provide an effective anti-thrombotic effect to safely manage stroke patients without increasing the risk of bleeding, a significant complication associated with existing treatments.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Disclosure of the total number of voting rights and shares as of February 28, 2022" and explicitly states it is disclosing this information pursuant to French Commercial Code and AMF regulations. It provides a table detailing the number of shares and voting rights as of a specific date (February 28, 2022). This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory requirement, often related to changes in ownership thresholds or general capital structure updates. While it touches upon share capital, it is not a general financing announcement (CAP) or a transaction in own shares (POS), but rather a formal declaration of the current voting structure. This fits best under Major Shareholding Notification (MRQ) as it deals with the total count of shares and voting rights, which is a key input for major shareholder calculations, or potentially Regulatory Filings (RNS) if a more specific code isn't available. However, since it is a direct disclosure of the total number of voting rights and shares, which is a common requirement when thresholds are crossed or periodically, and it is not a general announcement of a dividend, management change, or earnings, it most closely aligns with the scope of notifications related to share structure and ownership reporting. Given the options, MRQ (Major Shareholding Notification) is the closest fit for a formal disclosure of total voting rights/shares, although DVA (Declaration of Voting Results & Voting Rights Announcements) is also plausible if this was related to a recent vote. Since it is a static disclosure of the total count as of a date, MRQ is selected as the most appropriate category for share structure reporting, though RNS remains a fallback. Upon review of the definitions, DVA is specifically for 'Official results from shareholder votes', which this is not. MRQ relates to 'Notification of changes in significant share ownership levels (crossing thresholds)'. Since this document reports the *total* number of rights, which is the basis for determining if a threshold has been crossed, it is a direct input to that process. If a more specific 'Total Share Capital Disclosure' existed, it would be used. Given the available codes, MRQ is the best fit for a formal disclosure related to the total share base used for ownership tracking.
2022-03-03 English
Inside Information / Other news releases
Earnings Release Classification · 98% confidence The document is a press release dated February 22, 2022, announcing positive results from the ACTIMIS phase 1b/2a clinical study for the drug glenzocimab in treating Acute Ischemic Stroke (AIS). It details the achievement of primary and secondary endpoints related to safety, tolerability, and efficacy, and includes quotes from management and investigators. This format—an initial announcement of key financial or operational results, often preceding a full report or presentation—aligns perfectly with the definition of an Earnings Release (ER), even though the subject is clinical trial results rather than quarterly revenue. Since the document is an announcement of results and includes a notice for a subsequent results presentation webinar, it is best classified as an initial results announcement. FY 2022
2022-02-22 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated February 22, 2022, announcing the positive results of a Phase 1b/2a clinical study (ACTIMIS) for the drug glenzocimab in treating acute ischemic stroke. It details safety and efficacy endpoints, quotes management, and announces a follow-up webinar. This content structure—announcing key clinical trial results and providing context/quotes—is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical progress. Since it is not a full annual report (10-K), a formal audit report (AR), or a transcript (CT), and it focuses on immediate financial/operational news (clinical trial success), the most appropriate classification is Earnings Release (ER), as these often include significant operational milestones alongside financial updates, or it could be classified as Regulatory Filing (RNS) if it were purely a regulatory disclosure. Given the focus on announcing key results and scheduling a presentation, ER is a strong fit, though RNS is a possibility if this is considered a general material event disclosure. However, in the context of biotech, clinical trial results announcements are often grouped with ERs or Investor Presentations (IP). Since it is a formal announcement of results, not just a presentation deck, ER is chosen as the primary category for immediate material news dissemination. FY 2022
2022-02-22 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Disclosure of the total number of voting rights and shares as of January 31, 2022" and explicitly references French Commercial Code and AMF (Autorité des Marchés Financiers) regulations regarding share capital and voting rights disclosure. It provides a table detailing the number of shares and voting rights as of a specific date (January 31, 2022). This type of mandatory periodic disclosure regarding the composition of share capital and voting power is best classified as a regulatory filing or a specific announcement related to share structure. Since there is no specific category for 'Total Voting Rights Disclosure', and it is a formal regulatory communication, it fits best under 'Regulatory Filings' (RNS) or potentially 'Declaration of Voting Results & Voting Rights Announcements' (DVA). DVA is typically for the *results* of a vote, whereas this is a statement of the *basis* for voting (total shares/rights). Given the context of mandatory disclosure under financial regulations, RNS is the most appropriate general regulatory fallback, although it is very close to DVA. However, looking closely at the definitions, DVA is for 'Official results from shareholder votes at any general meeting'. This document is a routine disclosure of the share count, not the result of a vote. Therefore, RNS (Regulatory Filings) is the most suitable classification for this mandatory, non-standard report type.
2022-02-07 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 janvier 2022" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of January 31, 2022). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of a specific date (31/01/2022). This content directly relates to changes in share capital structure and voting rights reporting, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it is a specific, recurring report on the total number of shares and voting rights, it is a direct disclosure of capital structure information. Given the options, 'SHA' (Share Issue/Capital Change) is the most specific fit for reporting the total number of shares and voting rights, although it is not a new issue, but a periodic update on the existing structure. If a more specific category for voting rights reports existed, it would be preferred. Comparing the definitions, 'SHA' covers capital structure changes. Since this is a mandatory monthly disclosure of the total share count and voting rights, it falls under the umbrella of capital structure reporting. It is not a dividend announcement (DIV), director dealing (DIRS), or major shareholding notification (MRQ). Given the focus on the total number of shares and voting rights, SHA is the most appropriate classification among the provided codes for capital structure reporting.
2022-02-07 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated February 2, 2022, announcing the results of a Phase 2 clinical study (GARDEN) for the drug glenzocimab in treating COVID-19 related ARDS. It details the study design, safety findings (good tolerance, no serious adverse effects), and efficacy results (no statistically significant difference from placebo on the primary endpoint). It also mentions ongoing analysis and future results expected for another study (ACTIMIS) related to ischemic stroke. This content—a detailed announcement of clinical trial results and management commentary—is characteristic of an Earnings Release (ER) or a specific clinical update. Since it is a formal announcement of key periodic results (clinical trial outcomes) rather than a full financial report (10-K or IR), and it is not a transcript (CT) or a general presentation (IP), the most fitting category is Earnings Release (ER), as these often include operational and clinical milestones alongside financial highlights, or it could be classified as Regulatory Filing (RNS) if it were purely regulatory. Given the focus on announcing study results and management discussion, ER is a strong fit, although it is not strictly a quarterly financial earnings report. However, in the context of biotech, major clinical updates often substitute for or are bundled with ERs. Since it is a formal announcement of results, and not just a link to a report (RPA), ER is the best fit among the provided options for a significant operational/clinical update. Q1 2022
2022-02-02 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.